An Open-Label, Multi-Center, Expanded Access Study of RAD001 in Patients With Metastatic Carcinoma of the Kidney Who Are Intolerant of or Have Progressed Despite Any AvailableVascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Novartis
- 08 Oct 2012 This trial has been completed in Germany, Austria, Czech Republic, Finland, Sweden, Hungary, Belgium, Greece, Italy, and Netherlands as reported by European Clinical Trials Database.
- 28 Apr 2012 Planned number of patients changed to 1000 as reported by European Clinical Trials Database record.
- 10 Oct 2010 Preliminary results presented at the 35th Congress of the European Society for Medical Oncology.